BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 29128865)

  • 21. Associations and prognostic implications of Eastern Cooperative Oncology Group performance status and tumoral LINE-1 methylation status in stage III colon cancer patients.
    Chen D; Wen X; Song YS; Rhee YY; Lee TH; Cho NY; Han SW; Kim TY; Kang GH
    Clin Epigenetics; 2016; 8():36. PubMed ID: 27051466
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
    Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
    Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Promoter Methylation of BRCA1, DAPK1 and RASSF1A is Associated with Increased Mortality among Indian Women with Breast Cancer.
    Yadav P; Masroor M; Nandi K; Kaza RCM; Jain SK; Khurana N; Saxena A
    Asian Pac J Cancer Prev; 2018 Feb; 19(2):443-448. PubMed ID: 29480000
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aberrant promoter methylation of RASSF1A gene may be correlated with colorectal carcinogenesis: a meta-analysis.
    Wang HL; Zhang Y; Liu P; Zhou PY
    Mol Biol Rep; 2014 Jun; 41(6):3991-9. PubMed ID: 24566684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ERCC1 and ERCC2 as predictive biomarkers to oxaliplatin-based chemotherapy in colorectal cancer patients from Egypt.
    Kassem AB; Salem SE; Abdelrahim ME; Said AS; Salahuddin A; Hussein MM; Bahnassy AA
    Exp Mol Pathol; 2017 Feb; 102(1):78-85. PubMed ID: 28088319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received postoperative chemotherapy.
    Han Y; Cai H; Ma L; Ding Y; Tan X; Liu Y; Su T; Yu Y; Chang W; Zhang H; Fu C; Cao G
    Eur J Cancer; 2013 Nov; 49(16):3420-30. PubMed ID: 23809767
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Promoter methylation of the RASSF1A gene may contribute to colorectal cancer susceptibility: a meta-analysis of cohort studies.
    Wang HL; Liu P; Zhou PY; Zhang Y
    Ann Hum Genet; 2014 May; 78(3):208-16. PubMed ID: 24621386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ERCC5 promoter polymorphisms at -763 and +25 predict the response to oxaliplatin-based chemotherapy in patients with advanced colorectal cancer.
    Chen J; Xie F; Chen K; Wang D; Jiang H; Li J; Pan F; Chen S; Zhang Y; Ruan Z; Huang H; Zou L; Liang H
    Cancer Biol Ther; 2009 Jul; 8(14):1424-30. PubMed ID: 19458483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Methylation of the RASSF1A promoter is predictive of poor outcome among patients with Wilms tumor.
    Ohshima J; Haruta M; Fujiwara Y; Watanabe N; Arai Y; Ariga T; Okita H; Koshinaga T; Oue T; Hinotsu S; Nakadate H; Horie H; Fukuzawa M; Kaneko Y
    Pediatr Blood Cancer; 2012 Sep; 59(3):499-505. PubMed ID: 22457227
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Association between RIPK4 relative copy number and prognosis of colorectal cancer patient after oxaliplatin-based chemotherapy].
    Peng K; Lin M; Wei Q; Li H; Zhang C; Xie R; Liu Z
    Zhonghua Wei Chang Wai Ke Za Zhi; 2015 Nov; 18(11):1111-4. PubMed ID: 26616804
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NKX6.1 hypermethylation predicts the outcome of stage II colorectal cancer patients undergoing chemotherapy.
    Chang SY; Kuo CC; Wu CC; Hsiao CW; Hu JM; Hsu CH; Chou YC; Shih YL; Lin YW
    Genes Chromosomes Cancer; 2018 May; 57(5):268-277. PubMed ID: 29363224
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Promoter hypermethylation of the tumor-suppressor genes RASSF1A, GSTP1 and CDH1 in endometrial cancer.
    Fiolka R; Zubor P; Janusicova V; Visnovsky J; Mendelova A; Kajo K; Lasabova Z; Plank L; Danko J
    Oncol Rep; 2013 Dec; 30(6):2878-86. PubMed ID: 24068440
    [TBL] [Abstract][Full Text] [Related]  

  • 33. K-ras mutations and RASSF1A promoter methylation in colorectal cancer.
    van Engeland M; Roemen GM; Brink M; Pachen MM; Weijenberg MP; de Bruïne AP; Arends JW; van den Brandt PA; de Goeij AF; Herman JG
    Oncogene; 2002 May; 21(23):3792-5. PubMed ID: 12032847
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitative promoter hypermethylation analysis of RASSF1A in lung cancer: comparison with methylation-specific PCR technique and clinical significance.
    Lee SM; Lee WK; Kim DS; Park JY
    Mol Med Rep; 2012 Jan; 5(1):239-44. PubMed ID: 21971684
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between RASSF1A promoter methylation and renal cell cancer susceptibility: a meta-analysis.
    Huang YQ; Guan H; Liu CH; Liu DC; Xu B; Jiang L; Lin ZX; Chen M
    Genet Mol Res; 2016 Apr; 15(2):. PubMed ID: 27173228
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DNA methylation markers and serum α-fetoprotein level are prognostic factors in hepatocellular carcinoma.
    Lin JC; Wu YC; Wu CC; Shih PY; Wang WY; Chien YC
    Ann Hepatol; 2015; 14(4):494-504. PubMed ID: 26019036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The relationship between RASSF1A gene promoter methylation and the susceptibility and prognosis of melanoma: A meta-analysis and bioinformatics.
    Shao C; Dai W; Li H; Tang W; Jia S; Wu X; Luo Y
    PLoS One; 2017; 12(2):e0171676. PubMed ID: 28207831
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and Efficacy of a Modified FLOX Adjuvant Regimen for Patients With Stage III Colorectal Cancer Treated in the Community.
    Protásio BM; Matutino A; Lage LV; Santana I; Ramos R; Sabbaga J; Capareli F; Saragiotto D; Riechelmann R; Hoff PM
    Clin Colorectal Cancer; 2017 Mar; 16(1):65-72. PubMed ID: 27515842
    [TBL] [Abstract][Full Text] [Related]  

  • 39. β-catenin interaction with NHERF1 and RASSF1A methylation in metastatic colorectal cancer patients.
    Schirosi L; Mazzotta A; Opinto G; Pinto R; Graziano G; Tommasi S; Fucci L; Simone G; Mangia A
    Oncotarget; 2016 Oct; 7(42):67841-67850. PubMed ID: 27765918
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Methylation level of the RASSF1A promoter is an independent prognostic factor for clear-cell renal cell carcinoma.
    Kawai Y; Sakano S; Suehiro Y; Okada T; Korenaga Y; Hara T; Naito K; Matsuyama H; Hinoda Y
    Ann Oncol; 2010 Aug; 21(8):1612-1617. PubMed ID: 20038516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.